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ABSTRACT
Introduction: Bath emollients are widely prescribed
for childhood eczema, yet evidence of their benefits
over direct application of emollients is lacking.
Objectives To determine the clinical and cost-
effectiveness of adding bath emollient to the standard
management of eczema in children
Methods and analysis: Design: Pragmatic open
2-armed parallel group randomised controlled trial.
Setting: General practitioner (GP) practices in England
and Wales. Participants: Children aged over 12 months
and less than 12 years with eczema, excluding inactive
or very mild eczema (5 or less on Nottingham Eczema
Severity Scale). Interventions: Children will be
randomised to either bath emollients plus standard
eczema care or standard eczema care only. Outcome
measures: Primary outcome is long-term eczema
severity, measured by the Patient-Oriented Eczema
Measure (POEM) repeated weekly for 16 weeks.
Secondary outcomes include: number of eczema
exacerbations resulting in healthcare consultations over
1 year; eczema severity over 1 year; disease-specific
and generic quality of life; medication use and
healthcare resource use; cost-effectiveness. Aiming to
detect a mean difference between groups of 2.0 (SD
7.0) in weekly POEM scores over 16 weeks
(significance 0.05, power 0.9), allowing for 20% loss
to follow-up, gives a total sample size of 423 children.
We will use repeated measures analysis of covariance,
or a mixed model, to analyse weekly POEM scores.
We will control for possible confounders, including
baseline eczema severity and child’s age. Cost-
effectiveness analysis will be carried out from a
National Health Service (NHS) perspective.
Ethics and dissemination: This protocol was
approved by Newcastle and North Tyneside
1 NRES committee 14/NE/0098. Follow-up will be
completed in 2017. Findings will be disseminated to
participants and carers, the public, dermatology and
primary care journals, guideline developers and
decision-makers.
Trial registration number: ISRCTN84102309.
BACKGROUND
Childhood eczema is very common, affecting
over 20% of children aged 5 years or under
at some point.1 Eczema can cause signiﬁcant
distress to children and their families due to
sleep disturbance and itch.2 3 Health and
societal costs of eczema are thought to cause
a similar economic burden to that for
asthma.4 5 The term atopic eczema (syn-
onymous with atopic dermatitis) is widely
used to denote a clinical phenotype, rather
than those who are truly atopic deﬁned by
the presence of IgE-speciﬁc antibodies to
common environmental allergens. In this
study, we use the term ‘eczema’ throughout
to refer to the ‘atopic eczema’ clinical
phenotype, in accordance with the recom-
mended nomenclature of the World Allergy
Organisation.6
Guidelines suggest that emollients form
the mainstay of treatment for eczema and
should be used regularly by all patients with
other treatments, such as topical corticoster-
oids, used in addition where necessary.7
Strengths and limitations of this study
▪ We are carrying out the first large trial to provide
evidence about the clinical and cost-effectiveness
of bath emollients in the treatment of childhood
eczema.
▪ Children will be randomised to either bath emol-
lients plus standard eczema care or standard
eczema care only.
▪ Primary outcome is long-term eczema severity,
measured by the Patient-Oriented Eczema
Measure repeated weekly for 16 weeks.
▪ The trial is ‘open label’ as it would not be pos-
sible to create a convincing placebo for bath
emollients, which many carers and children are
already familiar with.
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Emollients are thought to act by providing a protective
layer over the skin, decreasing moisture loss and occlud-
ing against irritants. There are three methods of applica-
tion of emollients: (1) leave-on (directly applied)
emollients, where emollients are applied to the skin and
left to soak in; (2) soap substitutes, where emollients are
used instead of soap or other washing products; and (3)
bath emollients (or bath additives), which are oil and/
or emulsiﬁers designed to disperse in the bath. All three
approaches are often used together.
While there is widespread clinical consensus on the
need for leave-on emollients and soap substitutes, there
is less agreement regarding the additional beneﬁts of
bath emollients. Despite this, they are widely prescribed
at a cost of nearly £25 million per year to the National
Health Service (NHS) in England.8 A previous system-
atic review has revealed no convincing evidence for the
use of bath emollients in the treatment of eczema.9 10
Available data consist of isolated case series and case
reports, with no controlled studies. No relevant trials
have been published since 200711 and trial registries
reveal no ongoing studies.
In addition to concerns about cost-effectiveness,
potential harms from using bath emollients include skin
irritation and greasier bath surfaces that can increase
the risk of slips and accidents (listed in the Summary of
Product Characteristics of leading brands). There is also
a concern that people who use bath emollients in place
of leave-on emollients are receiving substandard emolli-
ent therapy.10
The effectiveness of adding antiseptic agents to bath
emollients has also not been demonstrated. Two small
randomised studies12 13 compared ‘bath emollient’ with
‘bath emollient plus antiseptic’ on a range of outcomes,
but there were no signiﬁcant differences between
groups, including colony counts of Staphylococcus
aureus.14 For this reason, we chose to exclude bath emol-
lients which incorporate an antiseptic, because of the
absence of beneﬁt and possible increased risk of skin
irritation.15
Pragmatic clinical trials aim to test the effectiveness of
an intervention in a real-life setting in order to recruit a
study population that is as similar as possible to the
population on which the intervention is meant to be
used. Whereas an explanatory clinical trial aims to
answer the question, ‘Can this intervention work under
ideal conditions?’ a pragmatic approach seeks to answer
the question, ‘Does this intervention work under usual
conditions?’16 17 Features of pragmatic trials include:
that they use clinically important outcomes, commonly
participant-reported outcomes; that they include longer
term follow-up; and that participants are encouraged to
adhere to the intervention only to the extent that would
be anticipated in usual care.
Although relatively few pragmatic trials have been
carried out in dermatology,18 we felt that a deﬁnitive
pragmatic clinical trial, including outcomes of relevance
to participants and including long-term follow-up, was
the most appropriate design to address the question of
the effectiveness of bath emollients in addition to stand-
ard eczema care in everyday care. We chose an ‘open
label’ design as it would not be possible to create a con-
vincing placebo for bath emollients, which make the
bath feel ‘greasy’. We wished to design a trial with a clin-
ical outcome relevant to participants. In eczema, the
appearance of the skin does not always closely reﬂect
symptoms causing a major impact on the child and
family, such as sleep disturbance and itch.19 It was there-
fore particularly important to design a trial with a vali-
dated participant-reported primary outcome.
We aim to determine the clinical and cost-effectiveness
of adding bath emollient to the standard management
of atopic eczema in children, which includes regular
application of leave-on emollients with use of topical cor-
ticosteroids as required. The BATHE trial is a pragmatic
randomised open-label multicentre superiority trial with
two parallel groups and a primary outcome of long-term
control as measured by Patient-Oriented Eczema
Measure (POEM) weekly scores over 16 weeks. Children
will be randomised in a 1:1 ratio to either bath emolli-
ents plus standard eczema care or standard eczema care
only. This paper outlines the study protocol, in accord-
ance with the SPIRIT guidelines (Standard protocol
items; recommendations for interventional trials).20
METHODS
Study setting
The BATHE study will recruit participants registered at
approximately 100 general practices in Wales, West of
England and South-West England (list of practices will
be on study website when available). Practices will be
recruited through the local Clinical Research Networks
in England and The National Institute for Social Care
and Health Research in Wales. We aim to recruit prac-
tices that are broadly representative of UK primary care
in terms of practice size and sociodemographics.
Eligibility
Children are eligible to participate in the study if they
are aged over 12 months and less than 12 years with
eczema according to UK Diagnostic Criteria for Atopic
Eczema.21 We will exclude children with inactive or very
mild eczema, deﬁned as a score of 5 or less on
Nottingham Eczema Severity Scale (NESS),22 in order to
avoid ﬂoor effects. We will exclude children who usually
have a bath less than once per week.
Children will be excluded if they or their carers are
not prepared to be randomised to either intervention
group or if their carer is unable to give informed
consent or does not have sufﬁcient English to complete
the trial documentation. Children will be excluded if
they are currently participating in any other clinical trial.
If a family has more than one child who meets the eligi-
bility criteria, they will be asked to choose just one child
to participate in the trial, as it would be burdensome to
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have different bathing regimens within one family, as
many will bath their children together. See ﬁgure 1 for
participant timeline.
Interventions
Eligible children will be randomised 1:1 to either bath
emollients plus standard eczema care or standard
eczema care only. Standard eczema care in this study
constitutes usual general practitioner (GP) care, supple-
mented by evidence-based guidance. We will provide
basic information on eczema care at baseline to partici-
pants and GPs in the form of a booklet based on the
National Institute for Health and Care Excellence
(NICE) guidance7 (available on study website). Standard
care includes advice to regularly use leave-on emollients
plus intermittent topical corticosteroids if required.
Standard care of eczema in the UK is generally delivered
through 10 min consultations in primary care initiated
by carers. GPs in the study will continue to refer to
dermatology services when they feel this to be necessary.
In the UK, referral criteria include: diagnostic uncer-
tainty; eczema not satisfactorily controlled; child or carer
may beneﬁt from specialist advice on treatment
application.7
Baseline appointments will be carried out by a trial
coordinator at the participant’s GP surgery (or at their
home if surgery premises not available) and informed
consent/assent will be sought at this point. At the base-
line appointment, both groups will be given basic infor-
mation about eczema and will be given identical verbal
and written information on how to wash children with
eczema as soap avoidance is an important component of
eczema care. This information is also available on the
study website. We will ask all carers to either wash their
child with water alone or to use a leave-on emollient as a
soap substitute. If they have difﬁculties with this and
request to use an emollient wash product then they may
do so. Guidelines on frequency of bathing vary, but most
healthcare professionals advise daily bathing for children
with eczema23 and this advice is offered in our informa-
tion to carers.
Children allocated to receive bath emollients will
receive a prescription for a bath emollient from a GP in
the participating practice and we will ask the prescriber
to enter this as a ‘repeat’ prescription, so that carers
may obtain further supplies as necessary, reﬂecting usual
prescribing in UK primary care. Carers will be asked to
use bath emollients as prescribed or described on the
packaging, to reﬂect how they are used in usual practice.
The British National Formulary (BNF) lists 13 differ-
ent bath emollients, but in clinical practice, a few of
these are commonly prescribed. We will encourage par-
ticipating practices to prescribe one of the following pro-
ducts: Oilatum Fragrance Free Junior, Balneum bath oil
or Aveeno Bath Oil. These products account for the
majority of bath emollient prescriptions issued in the
UK8 and appear in local prescribing formularies for par-
ticipating centres. Participants may express a preference
for one brand of bath emollient over another, or if no
preference is expressed, the choice of prescription will
be determined by the GP. If children or carers wish to
change bath emollient during the trial then they may
change to an alternative within the three above, or
choose a different bath emollient if their GP is happy to
prescribe this. Prescribers will be asked to avoid bath
emollients that contain additional ingredients such as
antipruritics and antiseptics.
Intervention adherence
We will ask children and their carers to adhere to their
treatment allocation for a year. If they feel that the
eczema is deteriorating, we will ask carers to consult
their GP in the usual way in order to address whether
other treatments are necessary. We will encourage adher-
ence to treatment allocation by ensuring that participat-
ing general practices are committed to supporting the
study and receive clear advice regarding maintaining
treatment allocation wherever possible. As this is a prag-
matic trial we wish to evaluate the beneﬁt of emollient
use in everyday practice and, for this reason, will not
make additional efforts to ensure adherence to treat-
ment allocation in either group. We will assess adher-
ence to treatment allocation in questionnaires.
Figure 1 Flow of participants through the trial (GP, general
practitioner; NESS, Nottingham Eczema Severity Scale;
POEM, Patient-Oriented Eczema Measure; QoL, quality of
life).
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Outcomes
Primary outcome measure
Our primary outcome measure is difference between the
two treatment groups in long-term control as measured
by POEM scores captured weekly over the ﬁrst 16 weeks.
POEM is a patient-reported outcome based on symptoms
over the previous week which can be completed by the
child’s carer or the child themselves.24 POEM is the only
patient-reported outcome that demonstrated sufﬁcient
validity and repeatability in a systematic review of
outcome measures for eczema25 and has been recom-
mended as the preferred instrument for capturing
patient-reported symptoms in eczema trials by
the Harmonizing Outcome Measures for Eczema
initiative (http://www.homeforeczema.org). Our primary
outcome measure is based on repeated measures of
POEM data collected weekly over 16 weeks because this
reﬂects the impact of this relapsing and remitting
chronic condition better than comparing outcomes at a
single follow-up point. However, if weekly questionnaires
prove too burdensome for participants and there is exces-
sive missing data, we will consider change in POEM score
from baseline to 4 months as our primary outcome.
Because of the burden of weekly questionnaires on
participants, we have limited weekly data collection to
the ﬁrst 16 weeks of the trial for the primary outcome
assessment but follow-up will continue for 12 months.
Participants may choose to complete questionnaires
either online or by post. See table 1 for schedule of
observations.
Secondary outcome measures
Secondary outcomes include differences between groups
in POEM scores captured monthly over 12 months.
We will analyse differences between groups in number
of eczema exacerbations resulting in a primary health-
care consultation over 12 months measured by GP notes
review. Exacerbations will be deﬁned as consultations
where there is mention of eczema and topical steroid or
topical calcineurin inhibitor has been advised or pre-
scribed (see table 1 schedule of observations for further
detail). We will also measure dermatology referrals and
prescribing for eczema over 12 months by GP notes
review. We will assess service use and medication use by
carer report, in addition to GP notes review.
We will ask both groups about use of bath emollient in
order to assess adherence to treatment allocation.
Adverse effects of bathing, such as stinging in the bath
or slipping in the bath or bathroom will also be asked in
both groups to allow exploration of any differences
between groups.
Differences between groups in change from baseline
in disease-speciﬁc quality of life at 4 and 12 months will
be measured by Dermatitis Family Impact (DFI). DFI26
is a widely used validated instrument measuring impact
of eczema on the family’s quality of life.
We will measure differences between groups in change
from baseline in generic quality of life at 4 and
12 months, using the Child Health Utility 9D
(CHU-9D).27 The use of EQ-5D in children has been
questioned and it does not capture quality of life issues
pertinent to childhood eczema. The CHU-9D is a paedi-
atric generic preference-based utility measure exclusively
developed with children aged 7–11 years and is more
suitable for capturing quality of life impact related to
eczema, such as sleep disturbance and child’s mood.
Personal communication with the team who developed
this measure conﬁrmed that studies are underway trial-
ling its application in children aged 5–7 years but, to our
knowledge, there are no studies reporting for infants.
There are no suitable utility measures validated for very
young children aged 1–4 years, but the CHU-9D per-
formed well in a similar population in the SPaCE feasi-
bility trial (CHU-9D data currently being prepared for
publication).28
We will use healthcare resource use data in order to
cost the intervention, collected by practice records, and
data collected by carer/parent-completed questionnaires
based on the modiﬁed Client Service Receipt Inventory
(CSRI).29
Sample size
The sample size was calculated for repeated measures
analysis of covariance (ANCOVA) in weekly POEM
scores over 16 weeks. Using data from a similar popula-
tion in the SWET trial,30 we aim to detect a mean differ-
ence of 2.0 (SD 7.0) between intervention and control
groups. An α of 0.05 and power 0.9 gives a sample size
of 338. Allowing for 20% loss to follow-up, this gives a
total sample size of 423 children.
Recruitment
Postal invitations to participate will be sent to the
parent/carer of children aged over 12 months and less
than 12 years who, by means of a search of their elec-
tronic medical records, are identiﬁed as having a diag-
nosis of eczema and who have obtained one or more
prescriptions for drugs acting on the skin over the previ-
ous 12 months (as a recent prescription would suggest
that the eczema is still active). Invitation packs may also
be given opportunistically by health professionals to
carers of children meeting these criteria.
Invitation packs contain an invitation letter on
GP-headed notepaper, participant information sheet, a
brief screening questionnaire and a reply slip to return
to the study team. The brief screening questionnaire
includes the NESS22 and questions to check that they
meet UK diagnostic criteria for eczema.21 The study
team will then contact carers to discuss the study further
and to conﬁrm eligibility criteria, before inviting them
to a recruitment appointment with a clinical studies
ofﬁcer at either their home or their GP practice.
Previous experience from the SPaCE feasibility trial28
suggests that we will obtain approximately seven partici-
pants from each general practice, and that approxi-
mately 60 practices will be sufﬁcient to recruit to target.
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We will increase or decrease the number of practices
participating on the basis of response rates to mail-outs
over the ﬁrst few months of recruitment.
METHODS
Assignment of interventions
Participants will be randomly allocated to treatment
group using computer-generated random sequence,
stratifying by region. Bath emollients make the bath feel
‘greasy’, and it is therefore not possible to make a con-
vincing placebo, particularly as a survey carried out
prior to the study suggested that many families of chil-
dren with eczema have experience of using bath emolli-
ent (see table 2). As discussed above, the main focus for
this pragmatic study is patient-centred, and primary
outcome is therefore a participant/proxy-reported score.
Care providers and clinical studies ofﬁcers will not be
blinded as they are involved in ensuring participants
receive the correct treatment and may be involved in dis-
cussing adherence with participants over the course of
the year. Furthermore, the additional staff cost that
would have been incurred by having researchers ‘blind’
to group allocation did not seem justiﬁable if the
primary outcome is participant-reported. The trial statis-
tician will remain blinded to treatment allocation.
Data collection methods
Data collection of participant-reported outcome mea-
sures will be carried out using online case report forms,
or paper case report forms if participants prefer this.
Participants will receive automated reminders by email
and text/short message service (SMS). If they do not
respond to this, then they will receive a telephone
reminder at key time points, such as the 16-week ques-
tionnaire. Participants will also be sent a £10 gift
voucher when the 16-week questionnaire is due and will
be entered into a prize draw when they have completed
the 52-week questionnaire.
Data collection from notes review will be carried out
by practice staff using standardised questionnaires.
Data management
Participants will enter their outcome data online into a
validated database. Data will be stored on a secure server
at the University of Southampton. Data collection from
notes review and from participants who prefer to com-
plete paper-based will be stored on paper in secure
ﬁling cabinets.
Statistical methods
We will use repeated measures ANCOVA to explore
whether there is a signiﬁcant difference between mean
POEM scores over the 16-week period in the interven-
tion and standard care groups. The analysis will control
for possible confounding effects of key covariates, such
as baseline eczema severity and age of child. However,
because ANCOVA relies on analysis of complete cases
only, the levels of missing data will be reviewed and, if
appropriate, the data will be analysed using mixed
Table 1 Schedule of observations
Outcomes collected Prescreen Baseline
Weekly for
15 weeks 16 weeks
4 weekly for
32 weeks 52 weeks
Carer-reported outcomes
UK diagnostic criteria for eczema ✓ ✓
Eczema severity over past year (NESS) ✓
Demographics ✓
Prior belief in bath emollients ✓ ✓ ✓ ✓
Service use ✓ ✓ ✓ ✓
Medication use ✓ ✓ ✓ ✓
Eczema severity over past week (POEM) ✓ ✓ ✓ ✓ ✓
Eczema-related quality of life (DFI) ✓ ✓ ✓
Generic quality of life (CHU-9D) ✓ ✓ ✓
Questions about washing ✓ ✓ ✓
Adverse effects from bathing ✓ ✓ ✓ ✓ ✓
Adherence/avoidance of bath emollients ✓ ✓ ✓ ✓
Review of GP records for 12 months from recruitment
Number of consultations* ✓
Referrals for eczema ✓
Medication use ✓
*Consultations will be categorised into the following four groups:
▸ Consultation record mentions flare of eczema or infected eczema or prescription or advice to use topical corticosteroids/calcineurin
inhibitors or antibiotics (topical or oral antibiotics for skin).
▸ Consultation record mentions eczema but with no indication that this was an eczema flare or infected eczema.
▸ Consultation record mentions skin rash, itch or dryness mentioned but no mention of eczema.
▸ Consultation recorded with no mention of eczema or skin rash, itch or dryness.
CHU-9D, Child Health Utility 9D; DFI, Dermatitis Family Impact; GP, general practitioner; NESS, Nottingham Eczema Severity Scale; POEM,
Patient-Oriented Eczema Measure.
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models instead, which allows incomplete cases to con-
tribute to the analysis. There will be no interim analyses.
For the analysis of secondary outcomes, repeated mea-
sures analysis in line with that used for the primary
outcome will be used for the monthly POEM measure
up to 1 year. For other secondary outcomes, linear
regression will be used for continuous outcomes if the
assumptions are met. Otherwise non-parametric analyses
will be used. Logistic regression will be used for dichot-
omous outcomes and a suitable count model, as
determined by goodness of ﬁt measures, for count data.
All analyses will control for potential confounders.
Primary analyses will be carried out on an intention to
treat basis, according to the CONSORT deﬁnition31
whereby all participants are included in the group to
which they were assigned, whether or not they com-
pleted the intervention given to the group. We will con-
sider carrying out a per protocol analysis in addition to
this if monitoring reveals a substantial proportion are
not following their treatment allocation (ie, intervention
group stop using bath emollient or control group start
bath emollient). We will carry out a sensitivity analysis
based on prior belief in bath emollients, to explore
whether this appears to have any inﬂuence on out-
comes. The statistical methods will be ﬁnalised in a stat-
istical analysis plan, which will be made available on the
study website.
Health economic analysis
The within trial economic analysis will include the
primary economic evaluation which will be in the form
of cost-effectiveness analysis. A secondary economic
evaluation in the form of cost-utility analysis will be con-
ducted using utility values obtained from the CHU-9D
preference-based quality of life measure. Although the
CHU-9D was not designed for use in very young chil-
dren, it has been used among children aged less than
5 (M Chorozoglou, personal communication). All cost-
effectiveness results will be presented on: (1) the cost-
effectiveness plane, which captures the uncertainty
around the results and shows the incremental cost and
incremental effect of the comparison of interest in a
two-dimentional plot, and (2) cost-effectiveness accept-
ability curves, which graphically represent the uncer-
tainty, in terms of probabilities, regarding the
cost-effectiveness of the new technology compared with
the existing alternative. The cost-effectiveness unit of
analysis will be: (1) the cost per unit change as mea-
sured by the primary outcome (POEM) at 16 weeks; (2)
cost per exacerbation avoided over 1 year. If the latter is
not possible then cost per unit score change of POEM
measure at 1 year will be reported.
Monitoring
The Trial Management Group is responsible for oversee-
ing progress of the trial. An independent Trial Steering
Committee will include Data Monitoring Committee
roles because the trial is investigating bath emollients,
used within their licensed range of indication, that are
available without prescription and have been used for
many years with no safety concerns. The Trial Steering
Committee includes independent experienced triallist,
medical statistician, dermatologist, and patient and
public representative, following a standard National
Institute for Health Research Health Technology
Assessment (NIHR HTA) charter. No interim analyses
are planned.
Table 2 Pretrial survey findings
How many times a week does your child have a bath?
(n=211)
Less than once a week 19 (9%)
1–2 times per week 47 (22.3%)
3–4 times per week 57 (27%)
5–6 times per week 25 (11.8%)
7 times per week 55 (26.1%)
More than 7 times per week 4 (1.9%)
How many times a week does your child have a shower?
(n=211)
Less than once a week 127 (60.2%)
1–2 times per week 39 (18.5%)
3–4 times per week 19 (9%)
5–6 times per week 5 (2.4%)
7 times per week 7 (3.3%)
More than 7 times per week 2 (0.9%)
What do you use to wash your child’s face, hands and
body? (n=209)
Emollient moisturiser 62 29.7%
Bath emollient 128 61.2%
Soap substitute 19 9.1%
Normal soap or body wash 21 10%
Water only 40 19.1%
Other 22 10.5%
What do you use to wash your child’s hair? (n=209)
Emollient moisturiser 7 3.3%
Bath emollient 23 11%
Normal shampoo 44 21.1%
‘Sensitive’ or fragrance free shampoo 101 48.3%
Water only 18 8.6%
Other 41 19.6%
Do you put bath emollients in your child’s bath? (n=207)
Yes, all the time 117 56.5
Yes, almost all the time 30 14.5
Yes, more than half the time 10 4.8
Less than half the time 14 6.8
Rarely 9 4.3
Never 27 13%
Do you think bath emollients help your child’s eczema?
(n=150)
Yes 69 46%
No 12 8%
Unsure 69 46%
We carried out an online survey in order to inform study design,
advertising through the National Eczema Society, Nottingham
Support Group for Carers of Children with Eczema and Centre of
Evidence-Based Dermatology. Carers were reporting about
children with median age 4 and mostly moderate or severe
eczema.
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Information about expected adverse reactions to bath
emollients which are listed in the Summary of Product
Characteristics (ie, pruritus, reddening, itching, skin irri-
tation, rash, accidental ingestion, slipping) will be col-
lected in trial questionnaires (or withdrawal form, where
applicable) and therefore need not be reported as an
adverse event. Any unexpected adverse event which
could reasonably have been caused by bath emollients
will be reported.
DISCUSSION
This will be the ﬁrst randomised controlled trial to inves-
tigate the role of bath emollients in the treatment of
childhood eczema. The results of the trial will be
important to families with eczema, primary care practi-
tioners, dermatologists, dermatology nurses, guideline
developers and decision-makers. We will disseminate the
ﬁndings to all these groups as widely as possible.
This study has strengths and weaknesses. The impossi-
bility of creating a convincing placebo for bath emolli-
ents means that it is not possible to carry out a blinded
study. The central importance of having a
participant-reported outcome measure for this prag-
matic trial means that perceptions of outcome may be
open to bias. We have mitigated for this by excluding
participants who express a strong preference either for
or against bath emollients, to the extent that they are
unwilling to accept randomisation, and we ask partici-
pants randomised to the trial about prior belief in the
effectiveness of bath emollients for eczema care, so that
we can carry out a sensitivity analysis to explore the
likely impact of such beliefs on the primary outcome.
A James Lind Alliance Priority Setting Partnership for
eczema identiﬁed a key priority from patients and carers
as ‘Which is the best way for people with eczema to
wash?’32 The role of bath emollients in the treatment of
childhood eczema was prioritised by the NIHR HTA
Programme, and this study aims to ﬁnd out whether
bath emollients are beneﬁcial for this condition.
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